Quest Diagnostics (DGX) Cash & Equivalents (2009 - 2026)

Quest Diagnostics has disclosed Cash & Equivalents across 18 years of filings, most recently posting $626.0 million for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 96.24% year-over-year to $626.0 million; the TTM figure through Jun 2026 stood at $626.0 million (up 96.24% YoY), while the FY2025 annual figure was $420.0 million, down 23.5% from the prior year.
• Cash & Equivalents came in at $626.0 million for Q2 2026 at Quest Diagnostics, up from $393.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $790.0 million in Q2 2022 to a low of $126.0 million in Q2 2023.
• Average Cash & Equivalents over 5 years is $449.1 million, with a median of $426.0 million recorded in 2025.
• Year-over-year, Cash & Equivalents slumped 84.05% in 2023 and surged 434.27% in 2024.
• Over 5 years, Cash & Equivalents stood at $315.0 million in 2022, then jumped by 117.78% to $686.0 million in 2023, then declined by 19.97% to $549.0 million in 2024, then retreated by 23.5% to $420.0 million in 2025, then soared by 49.05% to $626.0 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $626.0 million in Q2 2026, $393.0 million in Q1 2026, and $420.0 million in Q4 2025.